

United expertise for ChLIA diagnostics

Automated chemiluminescence immunoassay (ChLIA) systems are nowadays a mainstay for many diagnostic laboratories. Euroimmun has joined forces with Immunodiagnostic Systems (IDS) to offer an extensive portfolio of diagnostic solutions based on ChLIA technology. *Clinical Laboratory International* talked to Dr. Anna Stanisak, Global Product Manager for Automation at Euroimmun to find out more.

Why is ChLIA a central technology for laboratory diagnostics?

ChLIAs are widely favoured for analyte measurements due to their speed, accuracy and reliability. Luminometric detection by ChLIA typically offers higher sensitivity and a broader measurement range than chromogenic methods such as ELISA. For applications that are traditionally performed using radioimmunoassays, ChLIAs offer a fast, non-radioactive alternative.

The ChLIA technique enables fully automated assays, supporting high-throughput analyses with minimal manual intervention. Notably, its random-access capability allows for flexible and scalable testing without the constraints of batch processing. As a result, laboratories can significantly enhance the quality, efficiency and productivity of their daily testing.

How did you develop your extensive ChLIA portfolio?

Over recent years, we have significantly expanded our ChLIA product portfolio across all diagnostic areas. A key milestone in this journey was Immunodiagnostic Systems joining Euroimmun, both part of Revvity. IDS is a recognised leader in ChLIA technology, with expertise in a large range of diagnostic specialties. The integration has enabled us to offer our customers an exceptionally broad selection of high-quality ChLIAs complemented by state-of-the-art instrumentation designed to meet the demands of modern diagnostic testing. Our combined know-how provides a solid foundation for developing new assays based on novel targets. We also place a strong emphasis on personalised service, delivering comprehensive on-site training and technical support to our customers.

Which diagnostic specialties does your ChLIA range cover?

The ChLIA portfolio from Euroimmun and IDS spans a wide range of clinical indications across six core diagnostic specialties. Around 200 tests are currently available with many more in the pipeline.

Endocrinology is major area of strength of IDS, and the company has developed comprehensive test panels covering bone metabolism, growth disorders, reproductive health, hypertension and adrenal function. Notably, the IDS bone metabolism panel uniquely includes all recommended markers for monitoring osteoporosis therapy, also in patients with impaired kidney function. A recent highlight for the endocrinology portfolio was the free-testosterone ChLIA receiving US-FDA clearance this year – the first of its kind to do so. The IDS ChLIA menu also includes an extensive therapeutic drug monitoring range, manufactured by BIOSYNEX Theradiag. This covers a wide range of biologics and biosimilars and supports clinicians in optimising drug selection and dosage for individual patients.

In addition, we offer a large portfolio of ChLIAs for antibody detection in autoimmune diseases, infectious diseases and allergies. Both Euroimmun and IDS have extensive expertise in these diagnostic





areas, and we are continually expanding our product offerings to address evolving clinical needs. The portfolio is further complemented by assays for Alzheimer's disease biomarkers, helping laboratories to meet the growing demand in neuro-degenerative disease diagnostics.

Can different ChLIAs be run together on one instrument?

Yes, IDS fully automated systems allow laboratories to process multiple assays from different application areas in parallel. This gives laboratories exceptional flexibility in their daily testing routines and enables them to efficiently use the full capacity of their instrument.

Euroimmun and IDS offer three versatile random-access ChLIA analysers: the IDS-i10, the IDS-iSYS Multi-Discipline Automated System and the newly launched IDS i20. These offer test capacities of 10, 15, and 20 analytes, respectively, accommodating the varying needs of clinical laboratories. All three instruments provide fully automated processing with long walkaway times and minimal manual workload. For labs looking to streamline further, both the IDS-i10 and IDS i20 models can be integrated into a lab track.

The IDS i20 ChLIA analyser



Tell us about the new IDS i20

The IDS i20 is the latest model of the i-series and takes reagent and test capacity to a new level. It can simultaneously run 20 analytes from our six core diagnostic specialties, processing up to 140 tests per hour and delivering the first result in less than 25 minutes (depending on the assay). The instrument's compact footprint and extendable table make it particularly well-suited for laboratories with limited space. The IDS i20, along with the other i-series instruments, is developed and manufactured in-house, ensuring complete control over design, engineering and production quality.

The system software is also developed in-house by a collaborative IDS and Euroimmun team. It has been designed with modern cybersecurity standards in mind and meets the stringent IT policy requirements of healthcare institutions. At the same time, it is user-friendly and easy to navigate thanks to its intuitive graphical interface.

Is sustainability an important aspect?

Absolutely. IDS automated systems are built with both performance and environmental responsibility in mind. Factors such as reduced waste and electricity consumption are key considerations in instrument development, helping to lessen the environmental impact while delivering cost savings for our customers. This approach reflects our commitment to supporting greener laboratory operations without compromising analytical performance.

Where can readers find out more?

We welcome readers to visit www.euroimmun.com or www.idsplc.com to find out more about the ChLIA ranges and automation solutions or to contact a product specialist.

euroimmun 

From Revvity

Contact	EUROIMMUN AG
Address	Seekamp 31 23560 Luebeck Germany
Phone	+49 451 2032
Website	www.euroimmun.com